본 연구는 관상가치가 있는 자생 참두메부추와 갯부추를 절화소재로 이용하고자 수행되었다. 실험은 절화가 수확된 직후, gibberellic acid(GA3) 50, 75, 100mg·L-1, silver thiosulfate(STS) 0.1, 0.3, 0.5mM, 8-hydroxyquinoline sulfate(8-HQS) 25, 50, 100mg·L-1, 그리고 시중에 판매되 고 있는 Chrysal 8mL·L-1, Floralife 10mL·L-1의 보존용액 에 처리되었다. 참두메부추의 절화수명 연장에는 Chrysal 보 존용액 처리가 가장 효과적이었으며 다음으로 75mg·L-1 GA3 처리가 효과적이었다. 한편 8-HQS와 STS는 참두메부추의 절화수명을 단축하고 줄기가 갈변하는 등의 부정적인 영향을 끼쳤다. Chrysal과 더불어 Floralife 보존용액 처리는 절화 참두메부추의 상대 생체중변화율을 높이는데 효과가 있었다. 반면 갯부추는 100mg·L-1 GA3 처리에서 절화수명이 유일하 게 7일까지 연장되었다. GA3 보존용액 처리를 제외한 다른 처리에서 갯부추의 절화수명은 증류수인 대조구보다 비슷하 거나 약간 높은 수준이었다. 절화 갯부추의 수분흡수율은 실 험 초반 100mg·L-1 8-HQS 처리에서, 상대 생체중변화율은 Chrysal 보존용액 처리에서 가장 높게 조사되었으나 두 처 리 모두 절화수명이 유의하게 연장되지 않았다. 갯부추는 100mg·L-1 GA3 처리에서 절화수명을 비롯한 절화품질이 가 장 우수하였다.

흰꽃세덤(Sedum album)은 포복성으로 자라며 무리 지어 개화하는 특성을 가진 다육식물의 일종이다. 흰꽃세덤은 의약 품에 사용될 수 있는 플라보놀 배당체(flavonol glycoside)를 많이 생산하는 것으로 알려져 있다. 뿐만 비생물적 스트레 스 요인에 대해 강한 저항성을 가지고 있고 옥상녹화 시스템 (green roof systems)에 많이 사용되는 식물이다. 흰꽃세덤 은 강인한 생명력과 특이한 외형을 기반으로 실내에서 관상식 물로 사용될 수 있는 잠재력도 가지고 있다. 그러나 흰꽃세덤 이 실내식물로써 활용되기 위해서는 생장에 적합한 광질이 구명되어야 한다. 이에 따라 본 실험에서는 인공광원으로 시중 에 상용으로 판매되고 있는 3000, 4100, 6500K 백색 T5 LED를 사용하였으며 식물은 흰꽃세덤의 우량종인 ‘아툼’(S. album cv. Athoum)을 선발하여 본 실험에 적용하였다. 결과 적으로 초장, 초폭, 피복면적, 근장, 분지의 개수와 같은 식물 의 크기를 나타내는 지표는 4100K 백색 LED 처리구에서 크 게 증가하는 것으로 나타났다. 식물의 생체중과 수분함량은 4100K 백색 LED에서 증가하였으나 건물중은 3000K 백색 LED에서 증가하는 것으로 나타났다. CIELAB 중 명도를 나타 내는 L*은 4100K 백색 LED에서 가장 높게 나타났는데 이는 식물의 높은 수분함량으로 인한 세포의 팽창 혹은 에피큐티큘 러 왁스층(epicuticular waxes)의 발달로 추측되었다. CIE76 color difference(ΔE * ab)는 4100K 백색 LED 처리 구와 6500K 백색 LED 처리구 간에 ΔE* ab=5.51로 가장 크게 나타났다. RHS 분석에서는 모든 처리구가 동일하게 N137A, 147A로 평가되었다. 결론적으로 식물을 판매하거나 관상가치 를 향상시킬 목적으로 식물의 크기를 유의미하게 증대시키고 자 하는 경우 4100K 백색 LED를 사용할 것을 권고한다. 한 편, 살아있는 식물체를 약용으로 사용하거나 2차 대사산물을 추출하고자 하는 경우 4100K 백색 LED의 사용을 권고하며 말린 식물체를 활용하고자 한다면 3000K 백색 LED를 사용 할 것을 권고한다.

This study investigated changes in psychological stress levels of 60 firefighters after participation in an eight-week Equine-Assisted Learning (EAL) program consisting of 16 sessions. The Korean versions of the Posttraumatic Diagnosis Scale (PDS-K), the Center for Epidemiological Studies Depression Scale (K-CESD), and the Difficulties in Emotional Regulation Scale (K-DERS) were used for measurements. Participants were divided into two groups according to level of posttraumatic stress symptoms (PTSS): the PTSS risk group and the PTSS non-risk group. Results showed that PDS-K, K-CESD, and K-DERS scores were significantly reduced after the program in the PTSS risk group. Significant reduction was also found in all sub-scales of PDS-K: re-experiencing, avoidance/emotional numbing, and hyperarousal. Moreover, in the PTSS risk group, there were greater improvements with significant group x time interactions. These findings suggest that EAL is effective in relieving PTSD and PTSD-related symptoms of firefighters with subsyndromal or more severe levels of PTSD.

Following the previous study, the toxicity of a single subcutaneous administration of the Thyrokitty injection (I-131) and the side effects that may occur at therapeutic doses were confirmed. The Thyrokitty injection (I-131) was administered subcutaneously once at a dose of 0, 2.0, 6.0, and 18.0 mCi/kg, 5 male and female rats per group, and mortality, general symptom observation, and weight measurement were performed for 2 weeks, followed by observation of autopsy findings. There were no deaths, and no statistically significant weight change was observed. Mild hair loss, fissures, and crusting were observed by general symptom observation, but it was not a toxic change related to the Thyrokitty injection (I-131). Gastric atrophy and a decrease in the size of the spleen were observed by the autopsy. As a results of single subcutaneous administration of the Thyrokitty Injection (I-131) to rats at a maximum dose of 18.0 mCi/kg, a decrease in the size of the spleen and gastric atrophy were observed as the dose of the Thyrokitty Injection (I-131) increased, which may be related to the test substance. No abnormal findings related to the Thyrokitty injection (I-131) were observed. Therefore, the approximate lethal dose of the Thyrokitty injection (I-131) was 18.0 mCi/kg or more. In addition, as reported for the treatment of feline hyperthyroidism with radioiodine (131I), side effects of the Thyrokitty injection (I-131) are expected to be extremely rare. Temporary dysphagia and fever may occur, but it will recover naturally. It should be administered with caution in cats with diseases such as urinary system, cardiovascular system, gastrointestinal system and endocrine system, especially with kidney disease. And it should not be used in cats who are pregnant, lactating, or likely. It is expected that the Thyrokitty injection (I-131) can be used for clinical treatment in Korea as a veterinary drug.

Radioiodine (131I) has been used for the treatment of feline hyperthyroidism since the 1990s in the USA and Europe, and it is recommended as the most effective treatment for feline hyperthyroidism because it has a high therapeutic effect, small side effects, and does not require anesthesia. In this study, the pharmacological properties of the Thyrokitty injection (I-131), which is being developed as a treatment for feline hyperthyroidism, using radioiodine (131I) as an active ingredient, was tested. The %cell uptake of the Thyrokitty injection (I-131) in FRTL- 5 thyroid cells was 0.410 ± 0.016%, which was about 18 times higher compared to Clone 9 hepatocytes, and it was decreased by 30.7% due to the competitive reaction with iodine (sodium iodide). In addition, the %cell growth of the FRTL-5 thyroid cells was reduced by 25.0% by treatment with the Thyrokitty injection (I-131). As a result of the tissue distribution test, the Thyrokitty injection (I-131) was distributed at the highest concentration at 0.083 hours (5 minutes) after subcutaneous administration to animals in most organs except the stomach, small intestine, large intestine, muscle and thyroid gland, and it was excreted mainly through the kidneys. The stomach and thyroid gland showed a typical distribution pattern observed when radioiodine (131I) was administered. In addition, about 78.45% of the total amount of excretion was excreted within 48 hours, of which more than 85% was excreted in urine. In conclusion, the Thyrokitty injection (I-131) has the same mechanism of action, potency, absorption, distribution, metabolism and excretion characteristics as radioiodine (131I) reported in connection with the treatment of feline hyperthyroidism. In the future, using the results of this study, it is expected that the Thyrokitty (I-131) could be safely used in the clinical treatment of feline hyperthyroidism.